Dapagliflozin reduces the risk of new-onset diabetes mellitus, according to results from a pre-specified pooled analysis of the DAPA-CKD and DAPA-HF trials. The study adds to the growing list of sodium–glucose co-transporter 2 inhibitor benefits and raises the possibility of an expanded target patient population.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Nomura, S. et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J. Med. Chem. 53, 6355–6360 (2010).
Herrington, W. G. et al. Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors. Eur. J. Heart Fail. 23, 1260–1275 (2021).
Rossing, P. et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 10, 24–34 (2022).
Inzucchi, S. E. et al. Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care 44, 586–594 (2021).
Steven, S. et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 13, 370–385 (2017).
Folz, R. & Laiteerapong, N. The legacy effect in diabetes: are there long-term benefits? Diabetologia 64, 2131–2137 (2021).
Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021).
Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413–1424 (2020).
International Diabetes Federation. IDF Diabetes Atlas 10th edn (International Diabetes Federation, 2021); https://www.diabetesatlas.org
Cai, X. et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. Br. Med. J. 370, m2297 (2020).
D.V.O. receives support through an Australian Government Research Training Program Scholarship and an NHMRC Clinical Trials Centre Postgraduate Research Scholarship. M.J.J. is supported by a Medical Research Future Fund Next Generation Clinical Researchers Program Career Development Fellowship.
M.J.J. is responsible for research projects that have received funding from CSL, Dimerix, Eli Lilly and MSD and has received advisory, steering committee and/or speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL, Janssen, Merck, MSD, Roche and Vifor (all consultancy fees or honoraria are paid to her institution). D.V.O. declares no competing interests.
About this article
Cite this article
O’Hara, D.V., Jardine, M.J. SGLT2 inhibitors may prevent diabetes. Nat Rev Nephrol 18, 203–204 (2022). https://doi.org/10.1038/s41581-022-00541-8